Lv11
30 积分 2023-08-29 加入
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
1小时前
已完结
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
4小时前
已完结
Envafolimab: First Approval
7个月前
已完结
Ozoralizumab: First Approval
1年前
已完结
皖公网安备34019202002308
